Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Condition:   Renal Cell Carcinoma Interventions:   Drug: Nivolumab;   Drug: Ipilimumab Sponsor:   Kidney Cancer Research Bureau Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 22, 2019 Category: Research Source Type: clinical trials

Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Condition:   Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma Interventions:   Drug: Toripalimab;   Drug: Axitinib Sponsor:   RenJi Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 8, 2019 Category: Research Source Type: clinical trials

Observational Real-life Study of Cabozantinib in Advanced Renal Cell Carcinoma (RCC)
Condition:   Advanced or Metastatic Renal Cell Carcinoma Intervention:   Sponsor:   Ipsen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2019 Category: Research Source Type: clinical trials

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Condition:   Renal Cell Carcinoma Interventions:   Biological: Nivolumab;   Biological: Ipilimumab Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 12, 2019 Category: Research Source Type: clinical trials

AVEO Oncology Announces Updated Overall Survival Hazard Ratio Of 0.99 In Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 10, 2019-- AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s Phase... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 10, 2019 Category: Pharmaceuticals Source Type: clinical trials

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Condition:   Metastatic Renal Cell Carcinoma Intervention:   Drug: Sunitinib Sponsors:   Pfizer;   International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 2, 2019 Category: Research Source Type: clinical trials

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone
Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell C ancer AJCC v8;   Unclassified Renal Cell Carcinoma Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   O...
Source: ClinicalTrials.gov - August 27, 2019 Category: Research Source Type: clinical trials